Skip to main content

We continuously invest in the research on NeuroAiD, the findings are regularly published in specialized journals and released in international conferences.


Our team has worked with world renowned experts in over 20 research centres, and continues to forge academic partnerships to further explore its properties and promising benefits for new indications in neurology.


For more information, feel free to contact our medical team at [email protected]

Ischemic Stroke

  • NeuroAiD Danqi Piantang Jiaonang Does Not Modify Hemostasis, Hematology, and Biochemistry in Normal Subjects and Stroke Patients.

N.º de participantes: 64

Publicación: Gan R y cols. Cerebrovasc Dis 2008. DOI: 10,1159/000126919
  • NeuroAiD in Stroke Recovery. 

N.º de participantes: 10

Publicación: Siow C, Eur Neurol 2008. DOI: 10,1159/000155220

Ischemic Stroke

  • A Double-Blind, Placebo-Controlled, Randomized Phase II Pilot Study to Investigate the Potential Efficacy of the Traditional Chinese Medicine NeuroAiD (MLC601) in Enhancing Recovery after Stroke (TIERS).

Participation Size : 40

Sponsor : Moleac Pte Ltd.

Publicación: Kong KH y cols. Cerebrovasc Dis 2009.DOI: 10,1159/000247001
  • NeuroAiD (Danqi Piantang Jiaonang), a Traditional Chinese Medicine, in Poststroke Recovery.

Participation Size : 605

Sponsor : Tianjin University of Traditional Chinese Medicine

Publicación: Chen C y cols. Stroke 2009. DOI: 10.1161/STROKEAHA.108.531616

Traumatic Brain Injury – Neurosurgical pathologies

  • Case Report on the Use of MLC601 (NeuroAiD) in Neurosurgical Pathologies.

Publication: Yeo TT, et al. Poster WSC Seoul 2010.

Participation Size : 3

Ischemic Stroke

  • The effect of NeuroAiD (MLC601) on cerebral blood flow velocity in subjects’ post brain infarct in the middle cerebral artery territory.

N.º de participantes: 80

Publicación: Shahripour RB y cols. Eur Intern Med 2011. DOI: 10.1016/j.ejim.2011.01.002
  • NeuroAiD (MLC601) versus piracetam in the recovery of post-infarct homonymous hemianopsia. 

Participation Size : 40

Sponsor : Moleac Pte. Ltd.

Publicación: Ghandehari K y cols. Neural Regen Res 2011. DOI: 10.3969/j.issn.1673-5374.2011.06.003

Ischemic Stroke

  • The Use of NeuroAiD (MLC601) in Post ischemic Stroke Patients.

N.º de participantes: 30

Publicación: Navarro JC y cols. Rehabil Res Pract 2012. DOI: 10,1155/2012/506387
  • Safety and efficacy of MLC601 in Iranian patients after stroke: a double-blind, placebo-controlled clinical trial.

Participation Size : 150

Sponsor : Shahid Beheshti University

Publicación: Harandi AA y cols. Stroke Res Treat 2011. DOI: 10,4061/2011/721613

Ischemic Stroke

  • Chinese Medicine Neuroaid Efficacy on Stroke Recovery: A Double-Blind, Placebo-Controlled, Randomized Study.

Participation Size : 1099

Sponsor : CHIMES Society

Publicación: Chen C y cols. Stroke 2013. DOI: 10.1161/STROKEAHA.113.002055

Cognitive Disorders & Dementia

  • Efficacy and Tolerability of MLC601 in Patients with Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine.

Publication : Harandi AA, et al. Brit Med Med Res 2013.

Participation Size : 124

Sponsor : Shahid Beheshti University of Medical Sciences

Ischemic Stroke

  • A Randomized Trial to Assess the Long-Term Safety of NeuroAiD among Caucasian Patients with Acute Ischemic Stroke.

N.º de participantes: 150

Publicación: Shahripour RB y cols. Chin J Integr Med 2014. DOI: 10.1007/s11655-014-1687-8

Ischemic Stroke

  • CHInese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy.

Participation Size : 880

Sponsor : CHIMES Society

Publicaciones: Venketasubramanian N y cols. Cerebrovascular Diseases 2015. DOI: 10,1159/000382082

Cognitive Disorders & Dementia

  • Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer’s Disease: A Multicenter, Randomized Controlled Trial. 

N.º de participantes: 264

Publicación: Pakdaman, H y cols. Dementia and Geriatric Cognitive Disorders 2015. DOI: 10,1159/000375295

Ischemic Stroke

  • NurAiD-II in stroke recovery: scientific reasoning and real-world evidence.

Publication : De Le Cruz Cosme C. International Journal of Clinical Neurosciences and Mental Health 2017.

Cognitive Disorders & Dementia

  • MLC601 in vascular dementia: an efficacy and safety pilot study.

Participation Size : 81

Publicación: Pakdaman H y cols. Neuropsychiatric Disease and Treatment 2017. DOI: 10.2147/NDT.S145047
  • Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study. 

Participation Size : 72

Publicación: Pakdaman H y cols. Dementia and Geriatric Cognitive Disorders 2017. DOI: 10,1159/000458521

Traumatic Brain Injury – Neurosurgical pathologies

  • MLC901 (NeuroAiD) for cognition after traumatic brain injury: a pilot randomized clinical trial.

N.º de participantes: 78

Publicación: A. Theadom y cols. Eur J Neurol. 3 de abril de 2018. DOI: 10.1111/ene.13653

Ischemic Stroke 

  • Predictors of Neurological and Functional Recovery in Patients with Moderate to Severe Ischemic Stroke: The EPICA Study.

Publicación: Murie-Fernandez y cols. Hindawi Stroke Research and Treatment 2020.

Traumatic Brain Injury – Neurosurgical pathologies

  • Clinical Outcomes of MLC601 (NeuroAiD) in Traumatic Brain Injury: A Pilot Study.

Publicación: Fauzi AA y cols. Brain Sci 2020. DOI: 10.3390/brainsci10020060
  • MLC901 for Moderate to Severe Traumatic Brain Injury: Pilot, Randomized, Double-Masked, Placebo-Controlled Trial.

Publicación: Pakdaman H y cols. Open Access J of Complementary & Alternative Medicine. 2020 DOI: 10.32474/OAJCAM.2020.02.000148
  • Safety and Use of MLC601/MLC901 (NeuroAiD) in Primary Intracerebral Hemorrhage: A Cohort Study from the NeuroAiD Safe Treatment Registry.

Publicación: Kumar R y cols. Brain Sci 2020. DOI 10.3390/brainsci10080499

Spinal Cord Injury

  • Spinal cord injury – assessing tolerability and use of combined rehabilitation and NeuroAiD (SATURN) study – primary results of an exploratory study

Participation Size : 30

Publication: Kumar et al. The Journal of Spinal Cord Medicine. 2022 May 23.

Ischemic Stroke

  • Ischemic Stroke and Savings in Time to Achieve Functional Recovery: Experience from NeuroAiD

Participation Size : 548

Publication: Venketasubramanian, et al. Ischemic Stroke and Savings in Time to Achieve Functional Recovery 2023

Cognitive Disorders & Dementia

  • A long-term study of NeuroAid (MLC601, MLC901) in Patients with Alzheimer’s disease; An Extension 8-year Follow-up Study

Participation Size : 78

Publication: Pakdaman Hossein, et al. Alzheimer's Disease; An Extension 8-year Follow-up Study, Current Aging Science 2023

Spinal Cord Injury

  • Long-Term Outcomes of the Spinal Cord Injury Assessing Tolerability and Use of Combine Rehabilitation and NeuroAID (SATURN STUDY)

Participation Size : 30

Publication: Ramesh Kumar, et al. Journal of Spine Research and Surgery 2023
  • Spinal Cord Injury—Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD (SATURN Study): Protocol of An Exploratory Study In Assessing the Safety and Efficacy of NeuroAiD Amongst People Who Sustain Severe Spinal Cord Injury. 

Participation Size : 26

Sponsor : Moleac Pte. Ltd.

Publicación: Kumar JC y cols. JMIR Res Protoc 2016. DOI: 10.2196/resprot.6275
  • The NeuroAiD Safe Treatment (NeST) Registry: a protocol.

Participation Size : 460

Sponsor : CHIMES Society

Publicación: Venketasubramanian N y cols. BJM Open 2015. DOI: 10.1136/bmjopen-2015-009866
  • The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES).

Participation Size : 103

Sponsor : National University Hospital, Singapore

Publicación: Chen C y cols. Cerebrovasc Dis 2013. DOI: 10,1159/000346234
  • The Alzheimer’s disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer’s disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trial.

N.º de participantes: 125

Publicaciones: Chen CLHSharma PRVenketasubramanian N. Alzheimers Dement (N Y). Enero de 2019 23;5:38-45. DOI: 10.1016/j.trci.2018.12.001Low C

Exención de responsabilidad:  NeuroAiD™ II es una marca comercial de Moleac. MLC601 y MLC901 son 2 formulaciones patentadas diferentes cuya equivalencia farmacológica se ha demostrado y que se denominan NeuroAiD en esta página web.

Averigüe si NeuroAiD es el medicamento adecuado para su caso.

Para enviar sus preguntas a nuestro equipo de Atención al cliente, haga clic en el cuadro siguiente. En caso de duda, consulte siempre a su médico.

NAII 3 e1613530758649